%0 Journal Article
%A Sommerhäuser, Greta
%A Karthaus, Meinolf
%A Kurreck, Annika
%A Ballhausen, Alexej
%A Meyer-Knees, Johanna W
%A Fruehauf, Stefan
%A Graeven, Ullrich
%A Mueller, Lothar
%A Koenig, Alexander O
%A Weikersthal, Ludwig Fischer V
%A Goekkurt, Eray
%A Haas, Siegfried
%A Stahler, Arndt
%A Heinemann, Volker
%A Held, Swantje
%A Alig, Annabel H S
%A Kasper-Virchow, Stefan
%A Stintzing, Sebastian
%A Trarbach, Tanja
%A Modest, Dominik P
%T Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
%J International journal of cancer
%V 154
%N 5
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2023-02086
%P 863-872
%D 2024
%Z 2024 Mar 1;154(5):863-872
%X Despite molecular selection, patients (pts) with RAS wildtype mCRC represent a heterogeneous population including diversity in metastatic spread. We investigated metastatic patterns for their prognostic and predictive impact on maintenance therapy with 5-fluorouracil/folinic acid ± panitumumab. The study population was stratified according to (1) number of involved metastatic sites (single vs multiple organ metastasis), liver-limited disease vs (2) liver metastasis plus one additional site, and (3) vs liver metastasis plus ≥two additional sites. Kaplan-Meier method and Cox regressions were used to correlate efficacy endpoints. Single organ metastasis was observed in 133 pts (53.6
%K maintenance therapy (Other)
%K metastases (Other)
%K metastatic colorectal cancer (Other)
%K panitumumab (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37840339
%R 10.1002/ijc.34760
%U https://inrepo02.dkfz.de/record/284775